Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
WT1 encodes a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus. Additionally we are shipping WT1 Proteins (15) and WT1 Kits (13) and many more products for this protein.
Showing 10 out of 279 products:
Human Monoclonal WT1 Primary Antibody for WB - ABIN394194
Rocquain, Carbuccia, Trouplin, Raynaud, Murati, Nezri, Tadrist, Olschwang, Vey, Birnbaum, Gelsi-Boyer, Mozziconacci: Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. in BMC cancer 2010
Show all 5 references for ABIN394194
Human Polyclonal WT1 Primary Antibody for FACS, IF - ABIN655904
Sitaram, Degerman, Ljungberg, Andersson, Oji, Sugiyama, Roos, Li: Wilms' tumour 1 can suppress hTERT gene expression and telomerase activity in clear cell renal cell carcinoma via multiple pathways. in British journal of cancer 2010
Show all 5 references for ABIN655904
Human Monoclonal WT1 Primary Antibody for IHC, IHC (fro) - ABIN258719
Rauscher, Morris, Fredericks, Lopez-Guisa, Balakrishnan, Jost, Herlyn, Rodeck: Characterization of monoclonal antibodies directed to the amino-terminus of the WT1, Wilms' tumor suppressor protein. in Hybridoma 1998
Show all 4 references for ABIN258719
Human Polyclonal WT1 Primary Antibody for EIA, IF - ABIN955586
Dohi, Ohno, Ohno, Kyo, Soma, Sugiyama, Inoue: WT1 expression correlates with angiogenesis in endometrial cancer tissue. in Anticancer research 2010
Show all 4 references for ABIN955586
Human Polyclonal WT1 Primary Antibody for ELISA, WB - ABIN188555
Rao, Pham, Imam, MacLean, Murali, Furuta, Sinha-Hikim, Wilkinson: Tissue-specific RNAi reveals that WT1 expression in nurse cells controls germ cell survival and spermatogenesis. in Genes & development 2006
Mouse (Murine) Polyclonal WT1 Primary Antibody for IHC, WB - ABIN3021698
Sharma, Bowman, Madden, Rauscher, Sukumar: RNA editing in the Wilms' tumor susceptibility gene, WT1. in Genes & development 1994
Chicken Polyclonal WT1 Primary Antibody for IHC, WB - ABIN2780340
Ruteshouser, Robinson, Huff: Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. in Genes, chromosomes & cancer 2008
WT1 interference with Wnt (show WNT2 Antibodies) signaling represents an important mode of its action relevant to the suppression of tumor growth and guidance of development.
Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3 (show FLT3 Antibodies)-positive acute myeloid leukemia (show BCL11A Antibodies).
Wilms' tumor 1 is expressed in endometrial intra-epithelial neoplasia. Cellular endometrial intra-epithelial neoplasia Wilms' tumor 1 positivity was 100% and vascular Wilms' tumor 1 positivity was 85%. The endometrial adenocarcinoma group had 67% cellular Wilms' tumor 1 positivity and 73% vascular positivity.
WT1 localizes to the cytoplasm and mirn16-1 is decreased in nephrotic syndrome
WTI expression correlates with disease status both at the time of diagnosis and then different phases of the treatment. High WT1 burden in both these patients is indicative of early recurrence of the disease along with shorter disease-free and overall survival. The low WT1 expression (< 200 copies/ml) in 2 patients after induction and consolidation therapy respectively was suggestive of better prognosis.
miR (show MLXIP Antibodies)-361 was downregulated in NSCLC tissues and cell lines. Ectopic expression of miR (show MLXIP Antibodies)-361 suppressed the proliferation, migration and invasion of NSCLC cells via the direct targeting of WT1.
the results indicate that the cytoplasmic immunostaining does not correlate with actual WT1 expression and prompts researchers to carefully evaluate target molecule expression in treatment of cancer.
The Correlation between GATA5 (show GATA5 Antibodies), WT1 and PAX5 (show PAX5 Antibodies) methylation and clinical/histological parameters is suggestive of applicability of these markers in non-invasive (epi (show TFPI Antibodies))genetic testing in hepatocellular carcinoma (HCC (show FAM126A Antibodies)).
WT1 is often highly expressed in benign non-oncocytic salivary tumors whereas the malignant tumors show decreased expression, the exception being PLGA.
High WT1 expression is associated with leukemia.
WT1 was significantly under-expressed in testicular germ cell tumors. WT1 mutations occur frequently in testicular germ cell tumors.
Sodium butyrate-induced hyperacetylation up-regulates WT1 expression in porcine kidney fibroblasts, suggesting the involvement of histone acetylation in the transcriptional modulation of WT1 in porcine kidney cells.
Results indicate that WT1 plays important roles in the development of porcine preimplantation embryos, but not in oocyte maturation.
WT1 is expressed in porcine fetal fibroblasts, but the levels of expression were much lower compared to porcine primary kidney fibroblasts and swine testis, and WT1 is essential for the maintenance of development and survival of porcine fetal fibroblasts
Over expression of miR (show MLXIP Antibodies)-206 promotes podocyte injury via downregulation of WT1, which provides a new pathogenic mechanism for Focal segmental glomerulosclerosis and miR (show MLXIP Antibodies)-206 may be a potential therapeutic target.
by targeting WT1, miR743a suppresses the proliferation of MM cells in vitro, and probably possesses vital functions in kidney development and kidneyassociated diseases.
To test the tumorigenic potential of different cell types in the developing kidney, we used kidney progenitor-specific Cre recombinase alleles to introduce Wt1 and Ctnnb1 mutations, two alterations observed in Wilms tumor, into embryonic mouse kidney, with and without biallelic Igf2 expression, another alteration that is observed in a majority of tumors
miR (show MLXIP Antibodies)-125a is a regulatory molecule that suppresses WT1 expression via a direct interaction with the 3'UTR (show UTS2R Antibodies) of WT1 mRNA and miR (show MLXIP Antibodies)-125a knockout mice induce myeloproliferative disease (MPD (show MVD Antibodies)) and urogenital abnormalities
The analysis presented here demonstrates that WT1 regulates a broad set of genes, and almost 50% of the top 200 podocyte-specific genes-as defined in the GUDMAP gene expression atlas-were bound by WT1.
During normal heart development, spatio-temporal differences in contribution of WT-1 and Tcf21 (show TCF21 Antibodies)-LacZ (show GLB1 Antibodies) + cells to right versus left ventricular myocardium occur parallel to myocardial thickening.
Wt1 is essential for normal development at all kidney developmental stages under study.
Wt1 expression levels in podocytes regulate Wnt (show WNT2 Antibodies)/beta-catenin (show CTNNB1 Antibodies) signaling through modulating the endocytic fate of LRP6 (show LRP6 Antibodies), and this indicates a potential target for the therapy of CKD.
The results suggest a possible role for Wt1 in cardiac vessel formation in development and disease.
Conditional beta-catenin (show CTNNB1 Antibodies) loss phenocopies the Wt1 mutant diaphragm defect, while constitutive activation of beta-catenin (show CTNNB1 Antibodies) on the Wt1 mutant background is sufficient to close the diaphragm defect
While wt1a has a more fundamental and early role in pronephros development and is essential for the formation of glomerular structures, wt1b functions at later stages of nephrogenesis.
This gene encodes a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system, and it is mutated in a small subset of patients with Wilm's tumors. This gene exhibits complex tissue-specific and polymorphic imprinting pattern, with biallelic, and monoallelic expression from the maternal and paternal alleles in different tissues. Multiple transcript variants have been described. In several variants, there is evidence for the use of a non-AUG (CUG) translation initiation site upstream of and in-frame with the first AUG. Authors of PMID:7926762 also provide evidence that WT1 mRNA undergoes RNA editing in human and rat, and that this process is tissue-restricted and developmentally regulated.
Wilms tumor 1
, Wilms tumor protein homolog A
, Wilms tumor protein homolog
, Wilms tumor protein
, amino-terminal domain of EWS
, last three zinc fingers of the DNA-binding domain of WT1
, Wilm's tumor suppressor
, Wilms tumor protein homolog B
, Chick Wilm's tumour protein
, Wilms tumor suppressor protein 1b